8 pitch projects have already joined. Don't miss your last spot! Register in 60s to secure it.
2026 (2nd) EMT Bio-Manufacturing Industry Conference & Exhibition (Summer) Roadshow Registration Now Open!
8 27-28, the 2nd Yimao Bio-Manufacturing Industry Conference & Exhibition (Summer) will be held in Shanghai., the conference is organized byYimao MedicalHostShanghai Future Industry Bio-manufacturing Special Committee, Shanghai Society of BioengineeringTo support the unit,Blue Rainbow, Shanghai Synthetic Biology Innovation Strategic AllianceComprehensive coverage for partnersMedicine & Aesthetics, Bio-based Materials & Green Chemicals, Food & Agriculture, AI-Enabled SolutionsCore Areas.
Conference SettingsRoadshow SessionDeeply focused on cutting-edge trends and core development directions in biomanufacturing, providing a professional platform to precisely connect high-quality projects with capital. Founders, industry experts, and investors are invited to attend and exchange ideas to uncover new opportunities for industrial collaboration.
The first batch of project teams and mentors has already assembled!
Latest Roadshow Projects Overview
Project Name:Development and industrialization of bio-based platform chemicals (glucaric acid and 2,5-furanedicarboxylic acid) and their derivatives
Funding Round:Series A+
Key Highlights
Leveraging our proprietary, validated technology, we are building the world's first 10,000-ton FDCA flagship plant using glucose as the feedstock and glucaric acid as the intermediate. The process is compatible with idle PTA production lines, enabling low-cost, high-quality, continuous, and scalable manufacturing to lead the chemical industry's green and low-carbon transformation.
Project Name:Women's Health Small-Molecule Pharmaceuticals Targeting Multiple Nodes in Signaling Pathways
Roadshow Request:Seeking New-Co partnership: Raise capital for real-world evidence studies on innovative drugs; collaborate to obtain clinical trial approval and drive product commercialization.
Key Highlights
In the field of women's health where effective drugs are scarce, we integrate traditional Chinese medicine wisdom with modern biotechnology to enhance bioavailability and clarify signaling pathways. Leveraging our multi-target advantage, we inhibit HPV E6/E7, activate p53, and modulate epigenetics, HIF-α, and TGF-β. This approach induces apoptosis in HPV-infected mucosal cells, achieves HPV clearance, reverses precancerous lesions, and inhibits uterine fibroid proliferation, fibrosis, and nodules. With compliant product sales and robust clinical data on safety and efficacy, this innovative drug offers a low-risk, high-reward transformation path. Backed by independent intellectual property rights and patents granted in China, the US, and Europe, our research has been published in the Journal of Medical Virology.
Project Name:New Fully Automated Bioreactor
Funding Round:Series A
Key Highlights
Next-Gen Fully Automated Intelligent Bioreactor: Start with One Click, No Manual Intervention Required. Features a modular process library with fermentation protocols for E. coli, yeast, engineered strains, and more. The system automatically adjusts all parameters to enable true unattended operation.
Project Name:AI-Personalized Multi-Target Peptide Tumor Vaccine Combined with Enhanced NK Cell Immunotherapy Program
Roadshow Request:Clinical IIT Funding
Key Highlights
Established four proprietary core technology platforms: AI-based neoantigen prediction, multi-target polypeptide synthesis, sustained-release polysaccharide adjuvants, and enhanced NK cell preparation. Holding multiple authorized invention patents, we have developed an original polypeptide vaccine combined with NK cell synergistic therapy. Focusing on high-value, broad-spectrum tumor targets WT1 and MUC1, we fill the domestic gap in localized pipelines for personalized WT1/MUC1 polypeptide vaccines combined with NK cell therapy. Compared to existing therapies such as PD-1 and CAR-T, our solution offers differentiated advantages including lower side effects, controllable costs, and scalable production. It covers multiple solid tumors, including lung cancer, breast cancer, colorectal cancer, and liver cancer, forming a complete chain solution that integrates with clinical radiotherapy/chemotherapy and includes efficacy monitoring. Current progress: 1, collaborating hospitals for breast cancer trials; 2, animal studies are ongoing.
Project Name:The "Chip" of Bio-Based Furan New Materials: Industrial Breakthroughs and Blue Ocean Applications of 5-Hydroxymethylfurfural
Funding Round:Series B
Key Highlights
Breakthrough in 120+ 5-HMF production technologies, with the world's first 10,000-ton annual capacity line under construction. Secured over 2 billion RMB in funding and selected for a national key technology breakthrough program. Target costs reduced from 5 to below 2 per ton. Thousands of HMF derivatives are available, spanning bio-based plastics and fine chemicals, with global demand exceeding 10 million tons.
Project Name:Full Human Synthetic Library Phage Display Technology Development Platform and Industrialization
Roadshow Request:Fundraising for startups, co-development (Series A)
Key Highlights
This project establishes a high technical barrier through the world's first "library + AI" technology loop, an end-to-end team covering antibody discovery, development, and manufacturing, and strong industry-academia collaboration. We have built a global leading Fab synthetic phage library with a value of tens of billions, shortening the antibody R&D cycle to 1-1.5 months and reducing costs by 50% (150-200 ten thousand yuan). This significantly improves drug-likeness and screening efficiency, filling a critical technology gap in China.
Project Name:A leading domestic platform for biomanufacturing and application of rare traditional Chinese medicine components
Funding Round:Angel Round
Key Highlights
The company is dedicated to building China's most comprehensive platform for the bio-manufacturing and application of rare traditional Chinese medicine (TCM) ingredients. On one hand, we engineer microbial strains to produce multiple TCM components biologically; on the other, we have developed a fast-dissolving film dosage form that releases in 30 seconds for faster, more efficient oral absorption—positioning it as the next-generation platform for functional foods. This creates a commercial ecosystem combining bio-engineered active ingredients with innovative fast-dissolving film applications. To date, we have successfully achieved bio-manufacturing and commercial application of chondroitin sulfate, salidroside, ergothioneine, sialic acid, astaxanthin, ginsenosides, resveratrol, and other key compounds.
Project Name:End-to-end Customization and Industrialization of Hydrogenated Lecithin Production
Funding Round:Angel Round
Key Highlights
Leveraging molecular recognition-based separation and catalytic hydrogenation technologies, this solution offers a strong technical barrier and cost advantages. It meets the needs of the pharmaceutical, cosmetics, and food industries. The team boasts robust R&D capabilities. Selected for the "Nankong Elite" Program (Category A), the project will establish a pilot production line to drive domestic substitution of high-end excipients.
